Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis

Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis

Abstract Background Originator trastuzumab (Herceptin®; H) is an antibody-targeted therapy to treat patients with human epidermal growth factor receptor 2-positive (HER2+) early breast cancer (EBC). We investigated the overall survival (OS) advantage conferred by the addition of H to chemotherapy fo...

Full description

Bibliographic Details
Main Authors: Florence R. Wilson, Megan E. Coombes, Christine Brezden-Masley, Mariya Yurchenko, Quinlan Wylie, Reuben Douma, Abhishek Varu, Brian Hutton, Becky Skidmore, Chris Cameron
Format: Article
Language:English
Published: BMC 2018-11-01
Series:Systematic Reviews
Subjects:
Early breast cancer
HER2-positive breast cancer
Network meta-analysis
Survival
Systematic review
Trastuzumab
Online Access:http://link.springer.com/article/10.1186/s13643-018-0854-y

Internet

http://link.springer.com/article/10.1186/s13643-018-0854-y

Similar Items